J&J’s revenue grew by 5% to $23.4 billion. The gains were driven by a 6.3% rise in the company’s pharmaceutical sales and a 5.9% increase in medical device sales. A 1.5% decline in consumer health revenue, which was hurt by global supply chain disruptions, partly offset these gains.
“Our first-quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds,” CEO Joaquin Duato said in a press release.
All told, J&J’s adjusted earnings per share (EPS) increased 3.1% to $2.67. That was above Wall Street’s estimates, which had called for adjusted per-share profits of $2.58.
However, J&J cut its full-year guidance. Management now expects revenue of $94.8 billion to $95.8 billion, down from a prior projection of $95.9 billion to $96.9 billion. It also reduced its adjusted EPS forecast to a range of $10.15 to $10.35, down from $10.40 to $10.60.
Notably, J&J said it would suspend its guidance for COVID-19 vaccine sales due to a global supply surplus. But the company said that it does not earn a profit from these vaccine sales, so the change would not impact its adjusted earnings figures.
J&J’s proven ability to consistently generate profits in all manner of market environments prompted it to boost its quarterly cash dividend by 6.6%, to $1.13 per share. “In recognition of our 2021 results, strong financial position, and confidence in the future of Johnson & Johnson, the board of directors has voted to increase the quarterly dividend for the 60th consecutive year,” Duato said.
This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium advisory service. We’re motley! Questioning an investing thesis – even one of our own – helps us all think critically about investing and make decisions that help us become smarter, happier, and richer.